KMID : 0939920190510041549
|
|
´ëÇѾÏÇÐȸÁö 2019 Volume.51 No. 4 p.1549 ~ p.1556
|
|
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
|
|
Choi Yeon-Joo
Keam Bhum-Suk Kim Mi-So Yoon Shin-Kyo Kim Dal-Yong Choi Jong-Gwon Seo Ja-Young Park In-Keun Lee Jae-Lyun
|
|
Abstract
|
|
|
Purpose: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results for HLRCC-associated RCC. Based on these results, we analyzed the outcome of bevacizumab plus erlotinib in Korean patients with HLRCC-associated RCC.
Materials and Methods: We retrospectively reviewed the efficacy and safety of bevacizumab plus erlotinib in patients with HLRCC-associated RCC who were confirmed to have germline mutations in fumarate hydratase. The primary endpoint was the objective response rate (ORR), while the secondary endpoints were progression-free survival (PFS) and overall survival (OS).
Result: We identified 10 patients with advanced HLRCC-associated RCC who received bevacizumab plus erlotinib. Median age at diagnosis was 41 years, and five of the patients had received the combination as first- or second-line treatments. The ORR was 50% and the median PFS and OS were 13.3 and 14.1 months, respectively. Most adverse events were predictable and manageable by conventional measures, except for one instance where a patient died of gastrointestinal bleeding.
Conclusion: This is the first real-world outcome of the treatment of advanced HLRCC-associated RCC. Bevacizumab plus erlotinib therapy showed promising activity with moderate toxicity. We should be increasingly aware of HLRCC-associated RCC and bevacizumab plus erlotinib should be a first-line treatment for this condition, unless other promising data are published.
|
|
KEYWORD
|
|
Hereditary leiomyomatosis and renal cell carcinoma, Bevacizumab, Erlotinib, Renal cell carcinoma, Fumarate hydratase, Non-clear cell
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|